Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension

Clinical and Experimental Hypertension

Volumn 34, Issue 3, 2012, Pages 222-229

  Yigitaslan, Semra ^a   Sirmagul, Basar ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Monocrotaline; Pulmonary hypertension; Rat; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

BOSENTAN; ILOPROST; MONOCROTALINE; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HEART RIGHT VENTRICLE; NONHUMAN; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HYPERTENSION, PULMONARY; ILOPROST; MONOCROTALINE; PIPERAZINES; PULMONARY ARTERY; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; SULFONES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS;

EID: 84859782868     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.631652     Document Type: Article

References (48)

1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51:1527-1538. (Pubitemid 351508372)
2. Said SI. Mediators and modulators of pulmonary arterial hypertension. Am J. Phys.iol Lung Cell Mol Physiol 2006; 291:L547-L558. (Pubitemid 44498463)
3. Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiol Res 2000; 49:485-492.
4. Taraseviciene-Stewart L, Gera L, Hirth P, et al. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J. Phys.iol Pharmacol 2002; 80(4):269-274. (Pubitemid 34451241)
5. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension. Pharmacol. Ther. 2001; 92:1-20. (Pubitemid 34032020)
6. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S-24S. (Pubitemid 38759713)
7. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8:2129-2138.
8. Voelkel NF, Tuder RM. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Pulm Pharmacol. Ther. 1997; 10:231-241. (Pubitemid 29094833)
9. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44(1):14-30.
10. Howard LSGE, Morrell NW. New therapeutic agents for pulmonary vascular disease. Paed Resp Rev 2005; 6:285-291. (Pubitemid 41722611)
11. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Int Med 2005; 258:199-215. (Pubitemid 41243051)
12. Liu C, Liu K, Ji Z, Liu G. Treatments for pulmonary arterial hypertension. Resp Med 2006; 100:765-774.
13. Hoeper M, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am. J. Respir Crit Care Med 2002; 165:1209-1216. (Pubitemid 34461731)
14. Siobal MS. Pulmonary vasodilators. Respir Care 2007; 52(7):885-899.
15. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12):S56-S61.
16. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31:891-901.
17. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J. Phys.iol Lung Cell Mol Physiol 2002; 283: L555-L562.
18. Grover TR, Parker TA, Markham NE, Abman SH. rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J. Phys.iol Lung Cell Mol Physiol 2005; 289:L315-L321. (Pubitemid 41008915)
19. Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104:2242-2248. (Pubitemid 33043307)
20. Gong F, Tang H, Lin Y, et al. Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits. Pediatr Int 2005; 47:242-247. (Pubitemid 40827496)
21. Roth RA, Reindel JF. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv Exp Med Biol 1991; 283:477-487.
22. Wilson D, Segall HJ, Pan LC, et al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22(5-6):307-325. (Pubitemid 23014739)
23. Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 2006; 373(6):391-400. (Pubitemid 44401410)
24. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155(4):444-454.
25. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 1993; 46(6):1086-1091. (Pubitemid 23280552)
26. Partovian C, Adnot S, Eddahibi S, et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J. Phys.iol 1998; 275(6 Pt 2):H1948-H1956.
27. Boor PJ, Gotlieb AI, Joseph EC, et al. Chemical-induced vasculature injury. Summary of the symposium presented at the 32nd annual meeting of the Society of Toxicology, New Orleans, Louisiana, March 1993. Toxicol Appl Pharmacol 1995; 132(2):177-195.
28. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95(4):1798-1807.
29. Hoeper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am. J. Respir Cell Mol Biol 1997; 17(6):748-756. (Pubitemid 127348666)
30. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J. Phys.iol Lung Cell Mol Physiol 2006; 290:L209-L221.
31. Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am. J. Respir Crit Care Med 2000; 162: 1493-1499.
32. Rondelet B, Kerbaul F, Van Beneden R, et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 2004; 110(15):2220-2225. (Pubitemid 39372505)
33. Rondelet B, Kerbaul F, Motte S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003; 107(9):1329-1335. (Pubitemid 36314419)
34. Vidavalur R, Penumathsa SV, Zhan L, Thirunavukkarasu M, Maulik N. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Vascul Pharmacol 2006; 45(2):91-95. (Pubitemid 44374410)
35. Iglarz M, Silvestre JS, Duriez M, Henrion D, Lévy BI. Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-no pathway. Arterioscler Thromb Vasc Biol 2001; 21(10):1598-1603. (Pubitemid 34215578)
36. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001; 195(3):367-374.
37. Partovian C, Adnot S, Raffestin B, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am. J. Respir Cell Mol Biol 2000; 23(6):762-771. (Pubitemid 32013268)
38. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15(2):427-438. (Pubitemid 32141434)
39. Grover TR, Parker TA, Zenge JP, et al. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J. Phys.iol Lung Cell Mol Physiol 2003; 284(3):L508-L517. (Pubitemid 36231729)
40. Farkas L, Farkas D, Ask K, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119(5):1298-1311.
41. Fujita M, Mason RJ, Cool C, et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 2002; 93(6): 2162-2170. (Pubitemid 35379344)
42. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am. J. Pathol 1994; 144(2):286-295. (Pubitemid 24165949)
43. Park HK, Park SJ, Kim CS, et al. Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res 2001; 43(3):265-273. (Pubitemid 32601434)
44. Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104(7):790-795. (Pubitemid 32762677)
45. El-Haroun H, Clarke DL, Deacon K, et al. IL-1beta, BK, and TGF-beta1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA. Am J. Phys.iol Lung Cell Mol Physiol 2008; 294(3):L553-L562. (Pubitemid 351468855)
46. Markewitz BA, Farrukh IS, Chen Y, Li Y, Michael JR. Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor-beta and hypoxia. Cardiovasc Res 2001; 49(1):200-206.
47. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269(9):6271-6274. (Pubitemid 24190991)
48. Tzanidis A, Lim S, Hannan RD, et al. Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). JMol Cell Cardiol 2001; 33(5):969-981. (Pubitemid 32545331)